STOCK TITAN

Arcutis director Howard Welgus sells 4,728 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) director Howard G. Welgus exercised options for 4,094 shares on November 16, 2026, in three fully vested tranches: 822 shares at $6.5223, 1,018 at $7.5100, and 2,254 at $8.6300 per share. He also sold 4,728 common shares at $28.1600 per share. The reported transactions were made under a Rule 10b5-1 trading plan adopted March 13, 2026, with a plan end date of June 15, 2027.

Insider Welgus Howard G.
Role Director
Sold 4,728 shs ($133K)
Approx. gross sale proceeds $133K
Approx. exercise cost $32K
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1, F2 822 $0.00 $0.00
Exercise Stock Option (right to buy) F1, F2 1,018 $0.00 $0.00
Exercise Stock Option (right to buy) F1, F2 2,254 $0.00 $0.00
Exercise Common Stock F1 822 $6.5223 $5K
Exercise Common Stock F1 1,018 $7.51 $8K
Exercise Common Stock F1 2,254 $8.63 $19K
Sale Common Stock F1 4,728 $28.16 $133K
Holdings After Transaction: Stock Option (right to buy) — 24,562 options (Direct); Common Stock — 34,573 shares (Direct)
Footnotes (2)
  1. F1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
  2. F2. The option is fully vested.
Shares sold 4,728 shares November 16, 2026
Sale price $28.1600 per share November 16, 2026
Options exercised 822 shares At an exercise price of $6.5223 per share; November 16, 2026
Options exercised 1,018 shares At an exercise price of $7.5100 per share; November 16, 2026
Options exercised 2,254 shares At an exercise price of $8.6300 per share; November 16, 2026
10b5-1 trading plan regulatory
"transactions effected pursuant to a 10b5-1 trading plan"
A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.
fully vested financial
"The option is fully vested"
exercise price financial
"options exercised at the stated exercise prices"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARQT shares did Howard G. Welgus sell, and at what price?

Howard G. Welgus sold 4,728 shares at $28.1600 per share on November 16, 2026. The sale was made under a Rule 10b5-1 trading plan adopted March 13, 2026, with a plan end date of June 15, 2027.

What options did ARQT director Howard G. Welgus exercise?

Howard G. Welgus exercised fully vested options for 822 shares at $6.5223, 1,018 at $7.5100, and 2,254 at $8.6300 per share on November 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Welgus Howard G.

(Last)(First)(Middle)
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300

(Street)
WESTLAKE VILLAGE CALIFORNIA 91361

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M(1)822A$6.522336,029D
Common Stock11/16/2026M(1)1,018A$7.5137,047D
Common Stock11/16/2026M(1)2,254A$8.6339,301D
Common Stock11/16/2026S(1)4,728D$28.1634,573D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$6.522311/16/2026M(1)822 (2)11/20/2029Common Stock822$04,930D
Stock Option (right to buy)$7.5111/16/2026M(1)1,018 (2)05/31/2033Common Stock1,018$06,108D
Stock Option (right to buy)$8.6311/16/2026M(1)2,254 (2)06/14/2034Common Stock2,254$013,524D
Explanation of Responses:
1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
2. The option is fully vested.
Remarks:
/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading